Praxis Precision Medicines targets FDA approvals for two therapies by early 2027 and forecasts $10B peak sales for ulixacaltamide. Praxis Precision Medicines (PRAX) expects FDA decisions on two new drug applications within six months, aiming for approvals by early 2027. Th
German chemicals firm LANXESS reports Q2 EBITDA pre-exceptionals of EUR 152 million, up slightly from EUR 150 million a year ago. German specialty chemicals company LANXESS posted Q2 revenue of EUR 1.56 billion, a 6.48 percent year-over-year increase. EBITDA pre-exceptiona
WEN cuts dividend by 50% and pulls annual guidance as U.S. restaurant traffic and margins weaken under cost pressures. Wendy's new CEO announced a 50% dividend cut and withdrew full-year guidance after second-quarter results showed declining U.S. restaurant traffic. The co
The government services contractor cites a temporary halt in Veterans Affairs incentives for a reduced earnings forecast. Maximus lowered its fiscal 2026 adjusted earnings per share guidance to a range of $7.90 to $8.20, down by approximately $0.35. The reduction stems fro
The medical imaging firm reports Q2 2026 revenue of $3.9 million and reaffirms its full-year outlook while targeting a key regulatory submission. Hyperfine Inc. maintained its 2026 revenue guidance of $20M-$22M after posting $3.9 million in Q2 2026 revenue, its second-high
GTIM reports a year-over-year shift to positive same-store sales in Q3, signaling potential pricing strategy success. Good Times Restaurants Inc. (GTIM) announced a turnaround in same-store sales, marking a positive year-over-year shift in Q3 fiscal 2026. CEO Ryan Zink att
The company reported $9M in revenue for Q1, missing estimates by $0.97M despite a 57% jump in net income. Earth Science Tech posted Q1 revenue of $9 million, missing expectations by $0.97 million despite a 2.3% year-over-year increase. The company’s gross profit reached $6
The energy distributor reported stronger-than-expected earnings but missed revenue estimates for the second quarter of 2026. Global Partners posted a Q2 GAAP EPS of $1.86, exceeding expectations by $0.62. The result reflects improved profitability amid operational efficien
Dauch reports Q2 EPS of $0.32, beating estimates by $0.16, as revenue surges 92.2% year-over-year to $2.96B. Dauch posted second-quarter non-GAAP earnings per share of $0.32, exceeding estimates by $0.16, on revenue of $2.96 billion, a 92.2% year-over-year increase. The to
The biopharmaceutical firm reported a smaller-than-expected Q2 loss, driven by lower costs relative to estimates. Minerva Neurosciences posted a Q2 GAAP loss per share of $0.14, beating expectations by $0.06. The narrower loss reflects cost management amid ongoing research
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.